Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Third, payers have an opportunity to differentiate their competitive position through improving quality of care and health equity from maternal and neonatal health in their provider networks by utilizing the test |
| Sera is advantaged in its ability to leverage data set and portfolio of clinical research to provide information on the relative likelihood of specific outcomes or features of a pregnancy based on its proprietary predictive analytic algorithms |
| We're pleased with our progress last year and during the fourth quarter in laying out the foundation for future growth through key advancements in our PRIME and AVERT studies and product pipeline, all while controlling operating costs to ensure such growth is well-funded |
| With the key drivers of revenue in our business being publications validating our technology, signing on insurance payers, and broadening consumer and physician awareness of our products, we believe 2024 will be an exciting year for Sera with a number of expected catalysts and developments to support commercial expansion and shareholder value |
| Sera is uniquely positioned to contribute through our predictive analytics toolkits and testing solutions |
| Something like this usually doesn't happen, so we're highly encouraged that, following successful outcomes with our -REVENT PTB and AVERT studies, the interim PRIME readout may show similarly our test-and-treat approach enables better management and better health outcomes |
| One is, as I shared, there is a huge economic benefit of the test-and-treat strategy |
| To broaden the availability of our blood test and to also address underserved communities, we have made solid strides on PreTRM sample collection and assay enhancements, which will provide simpler, cheaper collection methods and more efficient lab processing |
| This should enable greater awareness of Sera beyond the medical community and allow us to provide more than one test to moms through convenient self-collection and generate more revenue through self-pay with a higher return on investment |
| Second, building awareness with expectant mothers and developing patient-facing products that can put us in direct contact with women and expand and diversify our revenue opportunities |
| You absolutely can expect to see us share more in the quarters ahead and we're excited by what's in store in 2024 |
| These results are quite compelling and encouraging and they have led to continuing conversations with prospective health insurance providers and the medical guideline community on the high-level findings |
| Specifically, we're delighted that there's a lot of interest in the results, as well as recommendations that the guideline-setting bodies are giving us on how to further our strategy to ensure the broader adoption and, therefore, evolution of the guidelines appropriately |
| We will continue to exercise diligent stewardship of our cash and invest opportunistically only in activities we believe could create additional value and have the greatest near and long-term revenue-generating potential |
| We're also engaging with employers, particularly self-insured employers, who are recognizing the tremendous value of including PreTRM Test in their benefit portfolio, not only because of cost savings and health outcomes from others and babies, but also because additional value in the ability to attract and retain parents as healthier babies increase presentism and the effectiveness of their parent workforce |
| In the next few months, we hope to have a powerful suite of accepted manuscripts, PREVENT-PTB, AVERT, and PRIME that demonstrate consistent clinically beneficial results |
| While we cannot control nor guarantee the timing of the publication, we are excited by the potential of publishing and, hopefully, in the near-term, on our PRIME and AVERT studies to back up the prior findings of the PreTRM-PTB study |
| Our platform, which enables unique pregnancy insights, has been instrumental in our activities to continue to progress our product pipeline beyond our commercially available PreTRM Test, with three products currently in later stages of development to build out our portfolio and diversify and support our revenue growth |
| We will update you on a quarterly basis of milestone achievements that we believe will position us well for a pivotal 2025 |
| At the same time, we hope to expand our product portfolio by the end of this year to deepen our relationship with our customers and diversify our revenue potential |
| In conclusion, the combination of the predictive analytics product and our blood test is expected to give unparalleled results not achievable with mRNA or any other technologies available, and should put us in an enviable competitive position when launched |
| Second, the payer should realize a lower cost of care as the benefits of healthier children are born |
| This initiative aims to address shortage in staff and equity of care across the country by providing stronger access to care, quality initiatives, and comprehensive risk appropriate screening and care solutions |
| Our PreTRM commercial strategy remains focused on generating publications showing evidence of the value of our tests, increasing contracts with insurance payers, and creating greater overall awareness |
| Launching this consumer-directed product should allow us to build a relationship with women earlier in their pregnancy and should be accretive to building adoption of Sera's clinical test PreTRM |
| Their coverage, to me, is a really critical prerequisite to drive physician adoption, and physician adoption is going to be a great vote of confidence for the guideline-setting bodies to change and evolve the guidelines |
| We anticipate the consumer convenience of self-collection could be a game-changer for PreTRM and other products we can bring to market for improving the maternal and neonatal experience |
| First, promoting to physicians, payers the growing evidence of the clinical utility of PreTRM to build adoption |
| This proteomics-enabled platform should allow us to take other products to market in the years ahead and offer us the opportunity to partner with or license our data to others in potentially high-value applications in maternal and neonatal health |
| We are on our way there in solidifying those drivers with our PreTRM business |
| Statement |
|---|
| Net loss for the fourth quarter of 2023 was $7.9 million, which was down from $9.7 million for the fourth quarter of 2022 |
| OB/GYNs and SMSMs are under strain in addressing a public health crisis of increasing maternal and neonatal mortality in the United States |
| It is a problem that needs urgent attention at the national level, especially when it comes to meeting the needs of underserved patients in healthcare deserts |
| Exceeding 2023's revenues by orders of magnitude, as is the current consensus expectation, would require achieving all of our key prerequisites in the first half of the year, which we think is highly uncertain |
| Total operating expenses for the fourth quarter of $8.9 million, were down significantly from $10.5 million for the same period a year ago due to steps we took to streamline commercial operations, better focus our commercial strategy, and reduce overall operating expenses |
| Selling, general and administrative expenses for the fourth quarter were $5 million and down significantly from $6.9 million for the same period a year ago, due to the steps we've taken to reduce expenses, while focusing on the best pathways to increase revenue in the quarters ahead |
| The result is that our total 2023 gross cash expenses came in at $33.7 million, consistent with our shared expectation of bringing this down to about $34 million for the year, and down significantly when compared to approximately $39 million for 2022 |
| Given the potentially breakthrough results we hope to report, we were urged to temper our desire to share more on PRIME and to take our time in publishing results in order to preserve the integrity of the publication |
| These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations for a variety of reasons |
| These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections and other forward-looking statements |
Please consider a small donation if you think this website provides you with relevant information